Raquibul Hannan, Michael J Dohopolski, Laurentiu M Pop, Samantha Mannala, Lori Watumull, Dana Mathews, Ang Gao, Aurelie Garant, Yull E Arriaga, Isaac Bowman, Jin-Sung Chung, Jing Wang, Kiyoshi Ariizumi, Chul Ahn, Robert Timmerman, Kevin Courtney
(1) We hypothesized that adding concurrent stereotactic ablative radiotherapy (SAbR) would increase the time to progression in patients with metastatic castrate-resistant prostate cancer (mCRPCA) treated with sipuleucel-T. (2) Patients with a history of prostate cancer (PC), radiographic evidence of metastatic disease, and rising prostate-specific antigen (PSA) > 0.2 ng/dL on castrate testosterone levels were enrolled in this single-arm phase II clinical trial and treated with sipuleucel-T and SAbR. The primary endpoint was time to progression (TTP)...
June 15, 2022: Biomedicines